Dr. Reddys Labs (RDY) Reports Q4 EPS of $0.47
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BofA/Merrill Lynch Downgrades Dr. Reddy's Laboratories (RDY) to Underperform
May 14, 2014 7:41 AM EDTBofA/Merrill Lynch downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Neutral to Underperform and cut their price target to $42.50 citing poor execution at the operational level.
Analyst Manoj Garg notes Dr Reddys (DRRD) 4Q PAT at Rs4.8bn (up 4% YoY) was -19% below the... More
Morgan Stanley Downgrades Dr. Reddy's Laboratories (RDY) to Equalweight
May 14, 2014 7:32 AM EDTMorgan Stanley downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Dr. Reddy's Laboratories click here. For more ratings news on Dr. Reddy's Laboratories click here.
Shares of Dr. Reddy's Laboratories closed at $43.82 yesterday.
... More